Abstract
Although elevated preoperative serum C-reactive protein (CRP) level is an indicator of a poorer prognosis in many cancers including non-metastatic bone and soft tissue sarcoma, there have been no reports focused on sarcoma patients with advanced stage who had distant metastases. The aim of this study is to determine whether the serum CRP level after metastasis is associated with post-metastatic survival in patients with bone and soft tissue sarcoma. A total of 71 patients were studied including 38 male and 33 female. Of all patients, 22 patients had metastases at presentation. The remaining 49 patients developed initial metastasis after the treatment of primary tumor. The average age at the diagnosis of metastasis was 55 years. Blood was obtained after initial detection of metastasis. CRP levels ranged from 0.1 to 165 mg/L with an average of 16.4 mg/L in all patients. Elevated CRP levels (>3 mg/L) were seen in 31 patients (range 3.1–165). The disease-specific survival after metastasis estimates at 3 and 5 years was 17.1 and 17.1 % for those with an elevated CRP vs. 59.5 and 45.3 % for those with a normal CRP (p < 0.0001). In 49 patients who developed lung metastasis after initial primary treatment, patients with elevated CRP levels also had a poorer post-metastatic survival than patients with normal CRP levels (p < 0.0001). In conclusion, we recommend routine measurement of CRP level to identify the patients who have high risk of death after metastasis.
Similar content being viewed by others
References
Kane III JM, Finley JW, Driscoll D, et al. The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases. Sarcoma. 2002;6:69–73.
Harting MT, Blakely ML, Jaffe N. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41:194–9.
Nakamura T, Matsumine A, Niimi R, et al. Management of small pulmonary nodules in patients with sarcoma. Clin Exp Metastasis. 2009;26:713–8.
van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675–82.
Weiser MR, Downey RJ, Leung HY, Brennan MF. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg. 2000;191:184–90.
Canter RJ, Lx Q, Downey RJ, Brennan MF, Singer S, Maki RG. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity. Cancer. 2007;110:2050–60.
Nakamura T, Matsumine A, Yamakado K, et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas. Cancer. 2009;115:3774–81.
Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality. A European study of 313 patients. Cancer. 2007;110:1241–7.
Kim DK, Oh SY, Kwon HC, et al. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9:155.
Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–44.
Nazoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001;182:197–201.
Nakamura T, Grimer R, Gaston C, et al. The value of C-reactive protein in predicting survival of patients with bone sarcoma. Bone Joint J. 2013;95-B:411–8.
Nakamura T, Grimer R, Gaston C, et al. The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma. Eur J Cancer. 2013;49:377–85.
Nakamura T, Matsumine A, Matsubara T, et al. Clinical significance of the pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 2012;118:1055–61.
Szkandera J, Gerger A, Liegl-Atzwanger B, et al. Validation of the prognostic relevance of plasma C-reactive protein levels in soft tissue sarcoma patients. Br J Cancer. 2013;109:2316–22.
Scott HR, McMillan C, Forrest LM, et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer. 2002;87:264–7.
Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028–30.
Woo Y, Hyung WJ, Obama K, et al. Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol. 2012;105:405–9.
Ito H, Shioi K, Murakami T, et al. C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patents most likely to benefit from initial nephrectomy. BMC Cancer. 2012;12:337.
Zeng YC, Xue M, Chi F, et al. C-reactive protein level predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy. Tumour Biol. 2012;33:891–5.
Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft-tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602–10.
van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675–682.
Nakamura T, Matsumine A, Matsubara T, et al. Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases. Clin Exp Met. 2011;28:819–25.
Joseph WL, Morton DL, Adkins PC. Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg. 1971;61:23–32.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Each author certifies that his institution has approved the human protocol for this investigation and that all investigations were conducted in conformity with the ethical principles of research.
Rights and permissions
About this article
Cite this article
Nakamura, T., Matsumine, A., Asanuma, K. et al. The role of C-reactive protein in predicting post-metastatic survival of patients with metastatic bone and soft tissue sarcoma. Tumor Biol. 36, 7515–7520 (2015). https://doi.org/10.1007/s13277-015-3464-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-3464-5